Overview

Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia

Status:
Completed

Trial end date:
2014-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the dose/response pharmacodynamic effects of ISIS ApoC-III Rx vs. Placebo on fasting total apoC-III levels.

Phase:

Phase 2

Details

Lead Sponsor:

Ionis Pharmaceuticals, Inc.